Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
(NYSE: ABBV) announced positive topline results from a phase 1 multiple ascending dose study evaluating ABBV-295, its long-acting amylin analog being developed for obesity and metabolic disease treatment
GLP-class compounds, secretagogues, and NNMT/NAD modulators studied for metabolic research
[ CrossRef] [ PubMed ] Damiano OM, Stevens AJ, Kenwright DN, Seddon AR
Semaglutide GLP-1 is an effective weight loss treatment that helps regulate appetite by mimicking a hormone in the body
Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B
US$ 29.80
US$ 28.94
US$ 20.96
US$ 29.85
US$ 28.72
US$ 25.86
